Read by QxMD icon Read

prostate cancer selenium

J A Lane, S E Oliver, P N Appleby, M A H Lentjes, P Emmett, D Kuh, A Stephen, E J Brunner, M J Shipley, F C Hamdy, D E Neal, J L Donovan, K-T Khaw, T J Key
BACKGROUND/OBJECTIVES: The influence of dietary factors remains controversial for screen-detected prostate cancer and inconclusive for clinically detected disease. We aimed to examine these associations using prospectively collected food diaries. SUBJECTS/METHODS: A total of 1,717 prostate cancer cases in middle-aged and older UK men were pooled from four prospective cohorts with clinically detected disease (n=663), with routine data follow-up (means 6.6-13.3 years) and a case-control study with screen-detected disease (n=1054), nested in a randomised trial of prostate cancer treatments (ISCTRN 20141297)...
September 28, 2016: European Journal of Clinical Nutrition
Phyllis J Goodman, Catherine M Tangen, Amy K Darke, Kathryn B Arnold, JoAnn Hartline, Monica Yee, Karen Anderson, Allison Caban-Holt, William G Christen, Patricia A Cassano, Peter Lance, Eric A Klein, John J Crowley, Lori M Minasian, Frank L Meyskens
BACKGROUND: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a randomized, double-blind, placebo-controlled, prostate cancer prevention study funded by the National Cancer Institute and conducted by SWOG (Southwest Oncology Group). A total of 35,533 men were assigned randomly to one of four treatment groups (vitamin E + placebo, selenium + placebo, vitamin E + selenium, placebo + placebo). At the time of the trial's development, NIH had invested substantial resources in evaluating the potential benefits of these antioxidants...
2016: Trials
Ingvild Paur, Wolfgang Lilleby, Siv Kjølsrud Bøhn, Erik Hulander, Willibrord Klein, Ljiljana Vlatkovic, Karol Axcrona, Nils Bolstad, Trine Bjøro, Petter Laake, Kristin A Taskén, Aud Svindland, Lars Magne Eri, Bjørn Brennhovd, Monica H Carlsen, Sophie D Fosså, Sigbjørn S Smeland, Anette S Karlsen, Rune Blomhoff
BACKGROUND & AIMS: The effect of lycopene-containing foods in prostate cancer development remains undetermined. We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients. METHODS: Prior to their curative treatment, 79 patients with prostate cancer were randomized to a nutritional intervention with either 1) tomato products containing 30 mg lycopene per day; 2) tomato products plus selenium, omega-3 fatty acids, soy isoflavones, grape/pomegranate juice, and green/black tea (tomato-plus); or 3) control diet for 3 weeks...
June 30, 2016: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
Naomi E Allen, Ruth C Travis, Paul N Appleby, Demetrius Albanes, Matt J Barnett, Amanda Black, H Bas Bueno-de-Mesquita, Mélanie Deschasaux, Pilar Galan, Gary E Goodman, Phyllis J Goodman, Marc J Gunter, Markku Heliövaara, Kathy J Helzlsouer, Brian E Henderson, Serge Hercberg, Paul Knekt, Laurence N Kolonel, Christina Lasheras, Jakob Linseisen, E Jeffrey Metter, Marian L Neuhouser, Anja Olsen, Valeria Pala, Elizabeth A Platz, Harri Rissanen, Mary E Reid, Jeannette M Schenk, Meir J Stampfer, Pär Stattin, Catherine M Tangen, Mathilde Touvier, Antonia Trichopoulou, Piet A van den Brandt, Timothy J Key
BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade. METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk...
November 2016: Journal of the National Cancer Institute
Eduardo H G da Cruz, Molly A Silvers, Guilherme A M Jardim, Jarbas M Resende, Bruno C Cavalcanti, Igor S Bomfim, Claudia Pessoa, Carlos A de Simone, Giancarlo V Botteselle, Antonio L Braga, Divya K Nair, Irishi N N Namboothiri, David A Boothman, Eufrânio N da Silva Júnior
UNLABELLED: Selenium-containing quinone-based 1,2,3-triazoles were synthesized using click chemistry, the copper catalyzed azide-alkyne 1,3-dipolar cycloaddition, and evaluated against six types of cancer cell lines: HL-60 (human promyelocytic leukemia cells), HCT-116 (human colon carcinoma cells), PC3 (human prostate cells), SF295 (human glioblastoma cells), MDA-MB-435 (melanoma cells) and OVCAR-8 (human ovarian carcinoma cells). Some compounds showed IC50 values < 0.3 μM. The cytotoxic potential of the quinones evaluated was also assayed using non-tumor cells, exemplified by peripheral blood mononuclear (PBMC), V79 and L929 cells...
October 21, 2016: European Journal of Medicinal Chemistry
June M Chan, Amy K Darke, Kathryn L Penney, Catherine M Tangen, Phyllis J Goodman, Gwo-Shu Mary Lee, Tong Sun, Sam Peisch, Alex M Tinianow, James M Rae, Eric A Klein, Ian M Thompson, Philip W Kantoff, Lorelei A Mucci
BACKGROUND: Epidemiologic studies and secondary analyses of randomized trials supported the hypothesis that selenium and vitamin E lower prostate cancer risk. However, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no benefit of either supplement. Genetic variants involved in selenium or vitamin E metabolism or transport may underlie the complex associations of selenium and vitamin E. METHODS: We undertook a case-cohort study of SELECT participants randomized to placebo, selenium, or vitamin E...
July 2016: Cancer Epidemiology, Biomarkers & Prevention
Tomasz Golabek, Jakub Bukowczan, Robert Sobczynski, Jaroslaw Leszczyszyn, Piotr L Chlosta
Prostate, bladder and kidney cancers remain the most common urological malignancies worldwide, and the prevention and treatment of these diseases pose a challenge to clinicians. In recent decades, many studies have been conducted to assess the association between supplementation with selected vitamins and elements and urinary tract tumour initiation and development. Here, we review the relationship between vitamins A, B, D, and E, in addition to calcium, selenium, and zinc, and the risk of developing prostate, kidney and bladder cancer...
April 1, 2016: Archives of Medical Science: AMS
Maarten C Bosland
The outcome of the Selenium and Vitamin E Cancer Prevention Trial, demonstrating harm and no preventive activity of selenomethionine and α-tocopherol for prostate cancer, and the lack of approval by the FDA for the use of 5α-reductase inhibitors to prevent prostate cancer have cast doubt about the future of chemoprevention of prostate cancer. This article attempts to critically assess whether the notion that chemoprevention of prostate cancer has no future is warranted. Risk of prostate cancer is modifiable and chemoprevention of prostate cancer, particularly fatal/lethal cancer, is both needed and possible...
August 2016: Cancer Prevention Research
Malene Outzen, Anne Tjønneland, Erik H Larsen, Søren Friis, Signe B Larsen, Jane Christensen, Kim Overvad, Anja Olsen
Low-Se status may be associated with a higher risk of notably advanced prostate cancer. In a Danish population with a relatively low Se intake, we investigated the association between pre-diagnostic Se status and (1) the risk of total, advanced and high-grade prostate cancer and (2) all-cause and prostate cancer-specific mortality among men with prostate cancer. Within the Danish 'Diet, Cancer and Health' cohort, including 27 179 men, we identified 784 cases with incident prostate cancer through 2007. Each case was risk set-matched to one control...
May 2016: British Journal of Nutrition
Zachary Hamilton, J Kellogg Parsons
Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer...
April 2016: Current Urology Reports
Verónica Alcolea, Daniel Plano, Deepkamal N Karelia, Juan Antonio Palop, Shantu Amin, Carmen Sanmartín, Arun K Sharma
A series of novel selenourea derivatives and corresponding thiourea analogs were synthesized and tested against a panel of six human cancer cell lines: melanoma (1205Lu), lung carcinoma (A549), prostatic carcinoma (DU145), colorectal carcinoma (HCT116), pancreatic epithelioid carcinoma (PANC-1) and pancreatic adenocarcinoma (BxPC3). In general, we found that the selenium-containing derivatives were more potent than their isosteric sulfur analogs. Four selenourea derivatives (1e, 1f, 1g and 1i) showed IC50 values below 10 μM in all of tested cell lines at 72 h...
May 4, 2016: European Journal of Medicinal Chemistry
Bhupendra Pal Singh, Shailendra Dwivedi, Urmila Dhakad, Ramesh Chandra Murthy, Vimal Kumar Choubey, Apul Goel, Satya Narayan Sankhwar
Deficiency or excess of certain trace elements has been considered as risk factor for prostate cancer. This study was aimed to detect differential changes and mutual correlations of selected trace elements in prostate cancer tissue versus benign prostatic hyperplasia tissue. Zinc, copper, iron, calcium and selenium were analysed in histologically proven 15 prostate cancer tissues and 15 benign prostatic hyperplasia tissues using atomic absorption spectrophotometer. Unpaired two tailed t test/Mann-Whitney U test and Pearson correlation coefficient were used to compare the level of trace elements, elemental ratios and their interrelations...
March 2016: Indian Journal of Clinical Biochemistry: IJCB
Wanling Xie, Ming Yang, June Chan, Tong Sun, Lorelei A Mucci, Kathryn L Penney, Gwo-Shu Mary Lee, Philip W Kantoff
BACKGROUND: Genetic variations in some of the selenoprotein genes, alone or together with an individual's selenium status, may influence risk or progression of prostate cancer. We investigated the impact of genetic variants of selenoproteins on plasma selenium levels and cancer aggressiveness at diagnosis in men with localized prostate cancer (PCa). METHODS: The study cohort comprised 722 patients seen at Dana-Farber Cancer Institute who had localized/locally advanced PCa (i...
May 2016: Prostate
Heather L Nakken, Edwin D Lephart, Tyler J Hopkins, Brett Shaw, Paul M Urie, Merrill J Christensen
BACKGROUND: Diets high in soy and selenium (Se) decrease prostate cancer risk factors in healthy rats. The purpose of this study was to determine whether treatment with high levels of soy and/or supplemental Se would decrease prostate cancer risk factors in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mouse, and whether timing of the introduction of these nutrients would affect risk reduction. METHODS: Male hemizygous [C57BL/6 × FVB]F1 TRAMP mice were exposed to stock diets high or devoid of soy, with or without a supplement of Se-methylselenocysteine (MSC) starting at conception (10 mg Se/L in drinking water of pregnant/nursing dams; daily bolus of 4 mg Se/kg body weight to pups after weaning) or at 6 weeks of age in a 2 × 2 factorial design...
May 2016: Prostate
Xianlei Cai, Chen Wang, Wanqi Yu, Wenjie Fan, Shan Wang, Ning Shen, Pengcheng Wu, Xiuyang Li, Fudi Wang
The objective of this study was to investigate the associations between selenium exposure and cancer risk. We identified 69 studies and applied meta-analysis, meta-regression and dose-response analysis to obtain available evidence. The results indicated that high selenium exposure had a protective effect on cancer risk (pooled OR = 0.78; 95%CI: 0.73-0.83). The results of linear and nonlinear dose-response analysis indicated that high serum/plasma selenium and toenail selenium had the efficacy on cancer prevention...
2016: Scientific Reports
Junxuan Lü, Jinhui Zhang, Cheng Jiang, Yibin Deng, Nur Özten, Maarten C Bosland
The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development...
2016: Nutrition and Cancer
Lei Wang, Xiaolan Guo, Ji Wang, Cheng Jiang, Maarten C Bosland, Junxuan Lü, Yibin Deng
Monomethylated selenium (MM-Se) forms that are precursors of methylselenol, such as methylseleninic acid (MSeA), differ in metabolism and anticancer activities in preclinical cell and animal models from seleno-methionine that had failed to exert preventive efficacy against prostate cancer in North American men. Given that human prostate cancer arises from precancerous lesions such as high-grade prostatic intraepithelial neoplasia (HG-PIN), which frequently have lost phosphatase and tensin homolog (PTEN) tumor suppressor permitting phosphatidylinositol-3-OH kinase (PI3K)-protein kinase B (AKT) oncogenic signaling, we tested the efficacy of MSeA to inhibit HG-PIN progression in Pten prostate-specific knockout (KO) mice and assessed the mechanistic involvement of p53-mediated cellular senescence and of the androgen receptor (AR)...
January 2016: Cancer Prevention Research
Maarten C Bosland, Nur Ozten, Jillian N Eskra, Abeer M Mahmoud
In this perspective, modifiable carcinogenic factors for the prostate are summarized. This is followed by a discussion of how current knowledge about causation of prostate cancer and chemoprevention of prostate cancer can be used to develop preventive strategies. Prostate cancer is a slowly developing cancer which offers opportunities for preventive interventions. Only a few randomized clinical trials of prostate cancer prevention have been completed. The SELECT study with selenium and vitamin E did not find protective effects, but in two trials with 5α-reductase inhibitors risk was reduced about 25%, showing that chemoprevention is possible and indicating that the androgen receptor is a suitable target...
August 1, 2015: Current Pharmacology Reports
A M Algotar, R Behnejad, P Singh, P A Thompson, C H Hsu, S P Stratton
OBJECTIVES: To determine the effect of selenium supplementation on the human proteomic profile. DESIGN: Serum samples were collected in this pilot study from a randomized placebo controlled Phase 2 clinical trial (Watchful Waiting (WW)). SETTING: Subjects were followed every three months for up to five years at the University of Arizona Prostate Cancer Prevention Program. PARTICIPANTS: One hundred and forty men (age < 85 years) had biopsy-proven prostate cancer, a Gleason sum score less than eight, no metastatic cancer, and no prior treatment for prostate cancer...
2015: Journal of Frailty & Aging
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"